BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res 2017;52:243-53. [PMID: 29333400 DOI: 10.5045/br.2017.52.4.243] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim SJ, Yoon DH, Kim JS, Kang HJ, Lee HW, Eom HS, Hong JY, Cho J, Ko YH, Huh J, Yang WI, Park WS, Lee SS, Suh C, Kim WS. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Res Treat 2020;52:374-87. [PMID: 31476851 DOI: 10.4143/crt.2019.198] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
2 Schneider H, Deweid L, Avrutina O, Kolmar H. Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates. Anal Biochem 2020;595:113615. [PMID: 32035039 DOI: 10.1016/j.ab.2020.113615] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
3 Knödler M, Buyel JF. Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions. Biotechnol Adv 2021;47:107683. [PMID: 33373687 DOI: 10.1016/j.biotechadv.2020.107683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Jimenez PC, Wilke DV, Branco PC, Bauermeister A, Rezende-Teixeira P, Gaudêncio SP, Costa-Lotufo LV. Enriching cancer pharmacology with drugs of marine origin. Br J Pharmacol 2020;177:3-27. [PMID: 31621891 DOI: 10.1111/bph.14876] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
5 Constantinescu C, Pasca S, Zimta AA, Tat T, Rus I, Teodorescu P, Iluta S, Tanase A, Colita A, Sigurjonsson O, Einsele H, Tomuleasa C. Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies. J Clin Med 2020;9:E2903. [PMID: 32911829 DOI: 10.3390/jcm9092903] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther 2018;11:4583-90. [PMID: 30122950 DOI: 10.2147/OTT.S141053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
7 Houen G. Therapeutic Antibodies: An Overview. Methods Mol Biol 2022;2313:1-25. [PMID: 34478129 DOI: 10.1007/978-1-0716-1450-1_1] [Reference Citation Analysis]
8 Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, Rassl DM, Fairen-Jimenez D, Rintoul RC, Nikolić MZ, Marciniak SJ. Biological basis for novel mesothelioma therapies. Br J Cancer 2021. [PMID: 34226685 DOI: 10.1038/s41416-021-01462-2] [Reference Citation Analysis]
9 Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. J Natl Cancer Inst 2019;111:538-49. [PMID: 30859213 DOI: 10.1093/jnci/djz035] [Cited by in Crossref: 101] [Cited by in F6Publishing: 90] [Article Influence: 101.0] [Reference Citation Analysis]
10 Carmon KS, Azhdarinia A. Application of Immuno-PET in Antibody-Drug Conjugate Development. Mol Imaging 2018;17:1536012118801223. [PMID: 30370812 DOI: 10.1177/1536012118801223] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
11 [DOI: 10.1101/2020.06.03.129049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Longjohn MN, Hudson JBJ, Smith NC, Rise ML, Moorehead PC, Christian SL. Deciphering the messages carried by extracellular vesicles in hematological malignancies. Blood Rev 2021;46:100734. [PMID: 32736879 DOI: 10.1016/j.blre.2020.100734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
13 Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist 2020;25:878-85. [PMID: 32720734 DOI: 10.1634/theoncologist.2020-0167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
14 Sanchez L, Dardac A, Madduri D, Richard S, Richter J. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Ther Adv Hematol 2021;12:2040620721989585. [PMID: 33796236 DOI: 10.1177/2040620721989585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Deweid L, Avrutina O, Kolmar H. Microbial transglutaminase for biotechnological and biomedical engineering. Biol Chem 2019;400:257-74. [PMID: 30291779 DOI: 10.1515/hsz-2018-0335] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]